This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
CAO/ARO/AIO-12 was a randomized phase 2 trial in patients with locally advanced rectal cancer. The study compared two sequences of preoperative treatment: induction chemotherapy followed by chemoradiotherapy, or chemoradiotherapy followed by induction chemotherapy, with surgery incorporated into the treatment strategy.
| Feature | CAO/ARO/AIO-12 |
|---|---|
| Phase | Phase 2 |
| Population | Patients with locally advanced rectal cancer, including Rectal Cancer Stage II and Rectal Cancer Stage III |
| Allocation | RANDOMIZED |
| Design model | SINGLE_GROUP |
| Masking | NONE |
| Primary purpose | TREATMENT |
| Enrollment | 311 |
| Number of arms | 2 |
| Trial status | COMPLETED |
| Lead sponsor | Prof. Dr. med. Claus Rödel |
| Sponsor type | OTHER |
| ClinicalTrials.gov | NCT02363374 |
2. Clinical Question
The central statistical question is whether the sequence of systemic chemotherapy and preoperative chemoradiotherapy affects the probability of achieving a pathological complete response before surgery in patients with locally advanced rectal cancer.
Population
Patients with locally advanced rectal cancer, with the registry identifying Rectal Neoplasms, Rectal Cancer Stage II, and Rectal Cancer Stage III as conditions.
Intervention sequence
Induction chemotherapy followed by preoperative chemoradiotherapy and surgery.
Comparator sequence
Preoperative chemoradiotherapy followed by induction chemotherapy and surgery.
Primary question
Does the sequence of induction chemotherapy and preoperative chemoradiotherapy affect the number of patients achieving pathological complete response, defined as ypT0N0?
3. Trial Design
The registry describes the allocation as RANDOMIZED, lists 2 arms, and identifies the primary purpose as TREATMENT. It also records the design model as SINGLE_GROUP and masking as NONE. These registry fields should be reported as recorded rather than replacing the registered design-model terminology with an inferred alternative.
Induction chemotherapy before chemoradiotherapy
- Induction chemotherapy
- Preoperative radiation treatment
- Preoperative chemoradiotherapy sequence
- Surgery
Chemoradiotherapy before induction chemotherapy
- Preoperative radiation treatment
- Preoperative chemoradiotherapy sequence
- Induction chemotherapy
- Surgery
4. Trial Timeline
Trial start
The registry records 2015-03-25 as the study start date.
Primary completion
The registry records 2018-09 as the primary completion date.
Registry status
The current registry information identifies the study status as COMPLETED.
5. Endpoints
| Endpoint | Registry definition | Time frame |
|---|---|---|
| Number of patients with pathological complete response (pCR) | Number of patients with pathological complete response (pCR), i.e. ypT0N0. | 123 +30 days |
The registry describes the primary endpoint as a count of patients achieving pathological complete response, with pCR defined as ypT0N0. The endpoint therefore concerns the pathological status assessed after the treatment sequence and surgery rather than a time-to-event outcome such as overall survival.
The registry description states that the endpoint addresses the efficacy of induction chemotherapy followed by chemoradiotherapy, or the other way round, before surgery in patients with locally advanced rectal cancer.
6. Why the Primary Endpoint Is Statistically Different From a Survival Endpoint
Pathological complete response is a binary patient-level outcome: each patient either meets the definition of ypT0N0 or does not. That makes the statistical structure different from endpoints such as overall survival or progression-free survival, where both the event time and censoring information contribute to the analysis.
Binary outcome
Each patient contributes to the pCR analysis according to whether the pathological definition ypT0N0 is achieved.
Between-arm comparison
Because the trial has two randomized arms, the principal comparison concerns the observed pCR proportion between the two treatment sequences.
No censoring framework
Unlike a Kaplan-Meier endpoint, a pCR analysis does not require a risk-set calculation for patients who remain event-free over time.
Clinical interpretation
A difference in pCR proportions describes pathological response under the randomized treatment sequences; it does not by itself establish a difference in long-term survival.
7. Planned Analysis
The registry identifies number of patients with pathological complete response (pCR), i.e. ypT0N0 as the primary endpoint, with a time frame of 123 +30 days. The registry does not contain posted statistical analyses for this endpoint.
For a binary endpoint such as pCR, the usual statistical analysis would compare the proportion of patients achieving ypT0N0 between the randomized treatment sequences. Depending on the prespecified statistical analysis plan and the observed cell counts, this type of comparison can be expressed as a difference in proportions, a relative measure such as a risk ratio, or an odds ratio, with an appropriate confidence interval and hypothesis test.
The treatment comparison asks whether the probability of achieving ypT0N0 differs between the two randomized sequences. The exact denominator and inferential procedure should follow the prespecified analysis population and statistical analysis plan.
Because no formal statistical analyses are posted to ClinicalTrials.gov, the registry does not provide an effect estimate, confidence interval, or p-value for the primary endpoint.
8. Statistical Methodology
Analysis of a binary endpoint
The pCR endpoint is naturally represented as a proportion. If \(x_A\) of \(n_A\) patients in one randomized sequence achieve ypT0N0, the observed pCR proportion is \(x_A/n_A\). The corresponding quantity can be calculated for the second sequence and compared directly.
A positive difference would indicate a higher observed pCR proportion in sequence A than sequence B, while a negative difference would indicate the opposite. The magnitude and uncertainty of the difference should be interpreted together.
Risk ratio
A risk ratio compares the probability of pCR in one randomized sequence with the probability in the other. A value of 1 indicates equal observed probabilities; values above or below 1 indicate relative differences in the corresponding direction.
The risk ratio is a relative measure. It should not be confused with an absolute difference in pCR probability.
Odds ratio
An odds ratio compares the odds of pCR rather than the probabilities themselves. For a binary outcome, the odds are \(p/(1-p)\). Odds ratios can be useful for two-group comparisons but can appear farther from 1 than the corresponding risk ratio when the outcome is not rare.
Confidence intervals
A confidence interval around a pCR effect estimate describes statistical uncertainty under the specified sampling and modeling framework. It is more informative than a point estimate alone because it shows the range of effect sizes compatible with the observed data under that framework.
Hypothesis testing
A conventional hypothesis test for two independent proportions evaluates a null hypothesis of no difference between treatment sequences. Depending on the prespecified method and sample-size conditions, a large-sample test or an exact method may be appropriate. The registry does not identify a specific inferential test in the information reported here.
9. Statistical Methods Explained
What does pCR mean statistically?
pCR is a binary endpoint based on pathological assessment. The registry defines it specifically as ypT0N0. The analysis therefore focuses on how many patients meet that definition in each randomized treatment sequence.
Why compare proportions rather than survival curves?
The registered primary endpoint is a count of patients with pCR, not a time-to-event endpoint. A survival analysis would require a different endpoint definition involving time until an event and censoring. Those elements are not part of the registered pCR definition.
What does a difference in pCR proportions mean?
If one sequence has a higher pCR proportion, the observed data would show a higher frequency of ypT0N0 under that sequence. The difference is an absolute measure, expressed in percentage points when proportions are reported as percentages.
What does a risk ratio mean?
A risk ratio compares probabilities rather than percentage-point differences. For example, an RR of 1.20 would mean that the observed probability of pCR was 20% higher on a relative scale in one group than the other. It would not mean a 20-percentage-point increase.
Why is the confidence interval important?
A point estimate alone does not show how precisely the trial estimates the treatment difference. A confidence interval provides a range of values compatible with the data under the specified statistical framework. Wider intervals indicate greater statistical uncertainty than narrower intervals.
Why does randomization matter for the pCR comparison?
Randomization assigns treatment sequence independently of patients' measured and unmeasured baseline characteristics, subject to chance variation. This is the key design feature supporting a causal comparison of the randomized sequences rather than merely an observational comparison of different patient groups.
10. Analysis Population and Missing Data Considerations
The registry information identifies enrollment and the primary endpoint but does not specify the detailed analysis population, handling of unevaluable pathological assessments, or missing-data method for the pCR analysis.
Denominator matters
A pCR proportion depends on the population included in its denominator. The statistical interpretation changes if the denominator is all randomized patients versus a narrower evaluable population.
Missing pathology
If pathological response cannot be assessed for some patients, the prespecified treatment of those observations can affect the estimated pCR proportion.
Randomization principle
An intention-to-treat analysis generally preserves the randomized comparison, while an evaluable analysis can answer a narrower question about patients with assessable outcomes.
Registry detail
The registry information available here does not specify which of these analysis conventions was prespecified for the primary endpoint.
11. Interpretation of the Trial Design
The central design feature is the comparison of treatment sequence. The two arms contain the same broad treatment components—chemotherapy, radiation, and surgery—but differ in whether induction chemotherapy occurs before or after preoperative chemoradiotherapy.
This is statistically important because the estimand is not simply "chemotherapy versus no chemotherapy." Both randomized sequences incorporate the registered treatment components. The clinically relevant contrast is the ordering of those components.
| Statistical feature | CAO/ARO/AIO-12 |
|---|---|
| Randomized allocation | Yes; registry field: RANDOMIZED |
| Number of arms | 2 |
| Masking | NONE |
| Primary purpose | TREATMENT |
| Primary endpoint type | Binary pathological response endpoint |
| Primary response definition | ypT0N0 |
| Registered time frame | 123 +30 days |
12. Why the Endpoint Definition Matters
The phrase ypT0N0 is more specific than a general statement such as "tumor response." The endpoint requires the pathological classification to satisfy both components of the definition: ypT0 and N0.
That distinction matters statistically because changing the response definition changes the event being counted. A clinical response assessed by imaging, for example, would not necessarily be interchangeable with a pathological complete response assessed after surgery.
The primary endpoint is a patient-level pathological state. A patient contributes to the pCR count when the registered pathological definition, ypT0N0, is met. The statistical comparison therefore concerns the frequency of this specific pathological outcome across the two randomized treatment sequences.
13. What the Registry Does and Does Not Establish Statistically
The registry establishes a randomized phase 2 treatment study with 311 enrolled patients, two arms, and a prespecified primary endpoint based on pathological complete response. It does not, in the information reported here, provide posted statistical analyses for that endpoint.
| Question | Registry information |
|---|---|
| How many patients were enrolled? | 311 |
| How many treatment arms were recorded? | 2 |
| Was allocation randomized? | Yes |
| Was masking used? | No |
| What was the primary endpoint? | Number of patients with pCR, i.e. ypT0N0 |
| What was the registered time frame? | 123 +30 days |
| Are statistical analyses posted? | No posted statistical analyses are recorded |
| Are primary endpoint estimates available in the registry information? | No |
14. Limitations
- No posted statistical analysis: the registry information does not contain a formal statistical analysis for the primary pCR endpoint.
- No reported effect estimate: the available registry information does not provide a pCR difference, risk ratio, odds ratio, confidence interval, or p-value.
- No detailed analysis population: the available information does not identify the exact denominator used for the primary pCR analysis.
- No missing-data specification: the available information does not describe how unevaluable or missing pathological assessments were handled.
- No subgroup analysis: subgroup estimates are not reported in the available registry information.
- No survival endpoint: the registered primary endpoint is pCR rather than overall survival or progression-free survival, so survival methods should not be substituted for the registered endpoint.
- Registry design-model terminology: the registry records the design model as SINGLE_GROUP while also recording randomized allocation and two arms. Those fields should be distinguished rather than silently reconciled into an alternative registry classification.
- No safety analysis: the available registry information does not provide arm-specific serious adverse-event results or a formal safety analysis.
15. Why This Trial Matters Statistically
CAO/ARO/AIO-12 is a useful statistical teaching example because the principal question concerns sequence optimization rather than a simple treatment-versus-placebo contrast. That changes how the randomized comparison should be described and interpreted.
| Concept | How it appears in CAO/ARO/AIO-12 |
|---|---|
| Randomization | The registry records RANDOMIZED allocation. |
| Two-arm comparison | The registry records 2 arms with different treatment sequences. |
| Unmasked treatment assignment | Masking is recorded as NONE. |
| Binary endpoint | The primary endpoint counts patients achieving ypT0N0. |
| Proportion comparison | The natural statistical representation is the pCR proportion in each randomized sequence. |
| Absolute effect | A difference in pCR proportions expresses the treatment-sequence contrast in percentage points. |
| Relative effect | A risk ratio or odds ratio can express the same binary comparison on a relative scale if prespecified. |
| Confidence intervals | They quantify uncertainty around the estimated binary treatment effect. |
| Analysis population | The choice of denominator can materially affect a binary response estimate. |
| Missing data | Unevaluable pathological outcomes require a prespecified analysis convention. |
16. Clinical Interpretation vs Statistical Interpretation
Statistical interpretation
The registered primary endpoint is a binary pathological outcome. The appropriate statistical question is whether the probability of ypT0N0 differs between the two randomized treatment sequences, with an effect estimate and uncertainty interval determined by the prespecified analysis.
Clinical interpretation
The endpoint is intended to evaluate pathological complete response after the different treatment sequences and surgery. A pCR comparison addresses that pathological outcome specifically and does not by itself describe every dimension of treatment efficacy or long-term clinical outcome.
17. A Practical Statistical Analysis Framework
For an independent statistical review of this type of trial, the analysis can be organized around four questions.
1. What is being counted?
The primary event is a patient achieving pathological complete response defined as ypT0N0.
2. Who is in the denominator?
The analysis population must be defined before calculating the pCR proportion. Randomized and evaluable populations can answer different questions.
3. What is the treatment contrast?
The comparison is between the two randomized sequences of induction chemotherapy and preoperative chemoradiotherapy.
4. How precise is the estimate?
A confidence interval around the treatment effect should accompany the point estimate so that the uncertainty of the comparison is visible.
18. Interpreting Statistical Significance Correctly
For a binary endpoint, a p-value—if reported in a formal analysis—would address evidence against a prespecified null hypothesis. It would not measure the magnitude of the treatment effect.
The effect estimate and confidence interval answer different questions. The estimate describes the observed contrast between treatment sequences, while the confidence interval describes uncertainty around that estimate under the chosen statistical framework.
A statistically small p-value would not by itself establish that the difference in pCR proportions is large or clinically important. Conversely, a wide confidence interval could indicate substantial uncertainty even when the point estimate appears notable.
19. What Would a Complete pCR Analysis Contain?
A complete statistical report for the registered primary endpoint would ordinarily identify the analysis population, provide the number and proportion of patients achieving ypT0N0 in each randomized arm, present an absolute between-arm difference or another prespecified effect measure, give a confidence interval, and report the corresponding hypothesis test if one was prespecified.
| Component | Purpose |
|---|---|
| Number with pCR | Shows the observed event count. |
| Analysis denominator | Defines the population from which the pCR proportion is calculated. |
| pCR proportion | Describes the absolute frequency of ypT0N0 in each arm. |
| Between-arm effect | Quantifies the difference or relative contrast between randomized sequences. |
| 95% confidence interval | Describes uncertainty around the estimated treatment effect. |
| Hypothesis test | Evaluates a prespecified null hypothesis if included in the statistical analysis plan. |
| Missing-data handling | Explains how patients without an evaluable pathological endpoint contribute to the analysis. |
20. Sources
- ClinicalTrials.gov: NCT02363374.
- PubMed: PubMed record for CAO/ARO/AIO-12-related publication.
- PubMed: PubMed record for CAO/ARO/AIO-12-related publication.
Continue through Clinical Biostats
Explore statistical tutorials, calculators, and additional clinical trial analyses across study designs and endpoint types.
21. Record Summary
CAO/ARO/AIO-12 is a randomized phase 2 treatment study enrolling 311 patients and recording 2 treatment arms. Its primary endpoint is the number of patients with pathological complete response (pCR), i.e. ypT0N0, with a registered time frame of 123 +30 days. Statistically, the endpoint is a binary pathological outcome, making comparison of pCR proportions the natural analytical framework. Interpretation depends on the prespecified analysis population, denominator, effect measure, confidence interval, hypothesis-testing procedure, and handling of unevaluable outcomes.